Global Musculoskeletal Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2017
No. of pages: 1000
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Musculoskeletal Partnering 2010 to 2017 provides the full collection of Musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Musculoskeletal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Musculoskeletal partnering agreement structure

Musculoskeletal partnering contract documents

Top Musculoskeletal deals by value

Most active Musculoskeletal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.

The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Musculoskeletal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Musculoskeletal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Musculoskeletal deals since 2010. Deals are listed by headline value. The

Chapter includes the top 25 most active Musculoskeletal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Musculoskeletal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Musculoskeletal partnering deals by specific Musculoskeletal target announced since 2010. The

Chapter is organized by specific Musculoskeletal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report scope

Global Musculoskeletal Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Musculoskeletal trends and structure of deals entered into by leading companies worldwide.

Global Musculoskeletal Partnering 2010 to 2017 includes:

Trends in Musculoskeletal dealmaking in the biopharma industry since 2010

Analysis of Musculoskeletal deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Musculoskeletal deal contract documents

Comprehensive access to over 3500 Musculoskeletal deal records

The leading Musculoskeletal deals by value since 2010

Most active Musculoskeletal dealmakers since 2010

The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthriti, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.

In Global Musculoskeletal Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Musculoskeletal Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Musculoskeletal Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Musculoskeletal deal trends since 2010

Access Musculoskeletal deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Musculoskeletal partner companies

Comprehensive access to over 750 links to actual Musculoskeletal deals entered into by the world's biopharma companies

Indepth review of Musculoskeletal deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Musculoskeletal opportunities

Uncover companies actively partnering Musculoskeletal opportunities

Global Musculoskeletal Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Musculoskeletal dealmaking
2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Musculoskeletal partnering
3.1. Introduction
3.2. Disclosed financials terms for Musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates

Chapter 4 - Leading Musculoskeletal deals and dealmakers
4.1. Introduction
4.2. Most active in Musculoskeletal partnering
4.3. List of most active dealmakers in Musculoskeletal
4.4. Top Musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory
5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Musculoskeletal therapeutic target

Appendices

Appendix 1 - Directory of Musculoskeletal deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Musculoskeletal deals by deal type 2010 to 2017
Appendix 3 - Directory of Musculoskeletal deals by stage of development 2010 to 2017
Appendix 4 - Directory of Musculoskeletal deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Musculoskeletal partnering since 2010
Figure 2: Musculoskeletal partnering by deal type since 2010
Figure 3: Musculoskeletal partnering by industry sector since 2010
Figure 4: Musculoskeletal partnering by stage of development since 2010
Figure 5: Musculoskeletal partnering by technology type since 2010
Figure 6: Musculoskeletal partnering by indication since 2010
Figure 7: Musculoskeletal deals with a headline value
Figure 8: Musculoskeletal deals with upfront payment values
Figure 9: Musculoskeletal deals with milestone payment
Figure 10: Musculoskeletal deals with royalty rates
Figure 11: Active Musculoskeletal dealmaking activity- 2010 to 2017
Figure 12: Top Musculoskeletal deals by value since 2010
  • Global Substance Abuse Treatment Market Research Report 2017
    Published: 19-Oct-2017        Price: US 2900 Onwards        Pages: 101
    In this report, the global Substance Abuse Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Substance Abuse Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe ......
  • United States Virus Like Particles Market Report 2017
    Published: 12-Oct-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • Global Virus Like Particles Sales Market Report 2017
    Published: 10-Oct-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Virus Like Particles for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Ja......
  • Heavy Metal Poisoning - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdomin......
  • Radiation Injury - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H2 2017, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure ca......
  • Low Back Pain - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 98
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2017, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in......
  • Binge Eating Disorder - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 62
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs ......
  • Global Microbiome Therapeutics Market Research Report 2017
    Published: 10-Oct-2017        Price: US 2900 Onwards        Pages: 127
    In this report, the global Microbiome Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Microbiome Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Sexual Dysfunction Partnering 2010 to 2017
    Published: 01-Oct-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Sexual Dysfunction Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs